Riociguat, marketed under the brand name Adempas, is a stimulator of soluble guanylate cyclase (sGC) indicated for the management of persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). By stimulating sGC, riociguat increases the production of cyclic guanosine monophosphate (cGMP), which helps relax and widen the blood vessels in the lungs. This lowers blood pressure in the pulmonary arteries, improving blood flow and reducing the workload on the heart. Riociguat is prescribed for patients with CTEPH who are inoperable or have recurrent/persistent hypertension after surgery, as well as for those with PAH to improve exercise capacity and delay disease progression.
![N-(4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)-N-methylacetamide](https://veeprho.com/wp-content/uploads/2025/11/N-46-diamino-2-1-2-fluorobenzyl-1H-pyrazolo34-bpyridin-3-ylpyrimidin-5-yl-N-methylacetamide-NA-VE0025716.png "N-(4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)-N-methylacetamide")
Parent: Riociguat
![N-(4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)-N-methylnitrous amide](https://veeprho.com/wp-content/uploads/2022/08/N-4-6-diamino-2-1-2-fluorobenzyl-1H-pyrazolo-3-4-b-pyridin-3-yl-pyrimidin-5-yl-N-methylnitrous-amide.png "N-(4,6-diamino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-5-yl)-N-methylnitrous amide")
Parent: Riociguat
Parent: Riociguat
Parent: Riociguat
Parent: Riociguat
Parent: Riociguat
Parent: Riociguat
Parent: Riociguat
![2-(1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidine-4,5,6- triamine](https://veeprho.com/wp-content/uploads/2025/03/VE0023175-2-1-2-Fluorobenzyl-1H-pyrazolo-3-4-b-pyridin.png "2-(1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidine-4,5,6- triamine")
Parent: Riociguat
![6-Amino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-7,9-dimethyl-7,9-dihydro-8H-purin-8-one](https://veeprho.com/wp-content/uploads/2025/03/VE0023176-6-Amino-2-1-2-fluorobenzyl-1H.png "6-Amino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-7,9-dimethyl-7,9-dihydro-8H-purin-8-one")
Parent: Riociguat
During the production and storage of riociguat, impurities can develop that must be carefully monitored to ensure the medication’s safety and efficacy. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) provide guidelines for acceptable impurity levels in pharmaceutical products to ensure patient safety.
Riociguat is used for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It helps to lower blood pressure in the lungs, improving blood flow and reducing the strain on the heart. Riociguat is particularly prescribed for patients with inoperable CTEPH or those who have recurrent hypertension after surgery.
Yes, riociguat is a vasodilator. By stimulating soluble guanylate cyclase (sGC), riociguat increases the production of cyclic guanosine monophosphate (cGMP), which relaxes the smooth muscles in the blood vessels, leading to vasodilation. This action helps reduce the pressure in the pulmonary arteries, improving blood flow and heart function.
Similar drugs to riociguat include other medications used to treat pulmonary arterial hypertension (PAH) and related conditions, such as bosentan (Tracleer), ambrisentan (Letairis), and macitentan (Opsumit), which are endothelin receptor antagonists. Additionally, sildenafil (Revatio) and tadalafil (Adcirca) are phosphodiesterase-5 (PDE5) inhibitors also used to treat PAH, but they work through different mechanisms compared to riociguat.
Yes, riociguat is FDA-approved for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It was approved in 2013 and is marketed under the brand name Adempas. Riociguat is the first FDA-approved drug for inoperable or persistent/recurrent CTEPH, and it is also approved for improving exercise capacity in PAH patients.
